Viatris Inc. (VTRS)

VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.

Viatris Inc. (NASDAQ:VTRS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andr...

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to...

Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.

Viatris (VTRS) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.69 per share a year ago.

Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some o...

VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.

VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.

As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. VTRS on Friday announced topline data from a Phase 3 study evaluating the effic...

The pharmaceutical company says its eye inflammation treatment didn't meet its target.